ALIN Trademark

Trademark Overview


On Tuesday, August 31, 2021, a trademark application was filed for ALIN with the United States Patent and Trademark Office. The USPTO has given the ALIN trademark a serial number of 97005028. The federal status of this trademark filing is REGISTERED as of Tuesday, September 10, 2024. This trademark is owned by Productos Farmaceuticos S.A. de C.V.. The ALIN trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, endocrinology for treatment of adrenal failure, thyroiditis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, rheumatology for treatment of rheumatoid arthritis, gout, post-traumatic arthritis, osteoarthritis, synovitis, bursitis, epicondylitis, ankylosing spondylitis, systemic or discoid lupus erythematosus, dermatomyositis, scleroderma, other collagen diseases, other osteoarticular diseases which require chronic corticosteroid administration; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alo...
alin

General Information


Serial Number97005028
Word MarkALIN
Filing DateTuesday, August 31, 2021
Status700 - REGISTERED
Status DateTuesday, September 10, 2024
Registration Number7498122
Registration DateTuesday, September 10, 2024
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateTuesday, June 25, 2024

Trademark Statements


Goods and ServicesPharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, endocrinology for treatment of adrenal failure, thyroiditis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, rheumatology for treatment of rheumatoid arthritis, gout, post-traumatic arthritis, osteoarthritis, synovitis, bursitis, epicondylitis, ankylosing spondylitis, systemic or discoid lupus erythematosus, dermatomyositis, scleroderma, other collagen diseases, other osteoarticular diseases which require chronic corticosteroid administration; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, dermatology for treatment of pemphigus, erythema multiforme, exfoliative dermatitis, psoriasis, contact dermatitis, keloid lesions, hyperthrophic lichen planus, alopecia areata, urticaria, eczema, rosacea; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, allergology for treatment of bronchial asthma, urticaria, drug or food allergy, hypersensitivity reactions, allergic rhinitis, allergic sinusitis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, otolaryngology for treatment of vasomotor rhinitis, other types of rhinitis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, ophthalmology for treatment of allergic, acute or chronic conjunctivitis, scleritis, uveitis, iridocyclitis, optic neuritis, corneal infections, keratitis, marginal ulcers, throphic disorders, conjunctival, corneal physical, chemical burning, and inflammatory reactions; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, gastroenterology for treatment of ulcerative colitis, regional enteritis; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, pulmonology for treatment of bronchoaspiration, Löeffler syndrome, sarcoidosis, interstitial pulmonary fibrosis, chronic bronchitis, emphysema; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, hematology for treatment of autoimmune anemias or thrombocytopenias, leukemias, lymphomas, intravascular coagulation syndrome; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, oncology for treatment of nausea and vomiting associated with cancer chemotherapy prevention; Pharmaceutical preparations, namely, corticosteroid with anti-inflammatory, immunosuppressive and anti-allergic actions, alone or in combination with other active pharmaceutical principles, for use in different therapeutic areas, namely, miscellaneous for treatment of shock syndromes, cerebral edema
Translation of Words in MarkThe English translation of "ALIN" in the mark is "lowest".

Classification Information


International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, November 8, 2022
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History


Party NameProductos Farmaceuticos S.A. de C.V.
Party Type30 - Original Registrant
Legal Entity Type03 - Corporation
AddressCiudad de México 11520
MX

Party NameProductos Farmaceuticos S.A. de C.V.
Party Type20 - Owner at Publication
Legal Entity Type03 - Corporation
AddressCiudad de México 11520
MX

Party NameProductos Farmaceuticos S.A. de C.V.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCiudad de México 11520
MX

Trademark Events


Event DateEvent Description
Thursday, October 14, 2021NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, September 3, 2021NEW APPLICATION ENTERED
Saturday, June 4, 2022ASSIGNED TO EXAMINER
Saturday, June 4, 2022NON-FINAL ACTION WRITTEN
Saturday, June 4, 2022NON-FINAL ACTION E-MAILED
Saturday, June 4, 2022NOTIFICATION OF NON-FINAL ACTION E-MAILED
Wednesday, November 30, 2022PRIORITY ACTION WRITTEN
Wednesday, November 30, 2022PRIORITY ACTION E-MAILED
Wednesday, November 30, 2022NOTIFICATION OF PRIORITY ACTION E-MAILED
Tuesday, May 30, 2023TEAS RESPONSE TO OFFICE ACTION RECEIVED
Tuesday, May 30, 2023CORRESPONDENCE RECEIVED IN LAW OFFICE
Wednesday, May 31, 2023TEAS/EMAIL CORRESPONDENCE ENTERED
Thursday, June 1, 2023SUSPENSION LETTER WRITTEN
Thursday, June 1, 2023LETTER OF SUSPENSION E-MAILED
Thursday, June 1, 2023NOTIFICATION OF LETTER OF SUSPENSION E-MAILED
Wednesday, November 29, 2023INQUIRY TO SUSPENSION E-MAILED
Wednesday, November 29, 2023SUSPENSION INQUIRY WRITTEN
Wednesday, November 29, 2023NOTIFICATION OF INQUIRY AS TO SUSPENSION E-MAILED
Monday, December 11, 2023TEAS RESPONSE TO SUSPENSION INQUIRY RECEIVED
Tuesday, April 30, 2024ASSIGNED TO LIE
Tuesday, April 30, 2024CORRESPONDENCE RECEIVED IN LAW OFFICE
Tuesday, April 30, 2024TEAS/EMAIL CORRESPONDENCE ENTERED
Friday, May 17, 2024APPROVED FOR PUB - PRINCIPAL REGISTER
Wednesday, June 5, 2024NOTIFICATION OF NOTICE OF PUBLICATION E-MAILED
Tuesday, June 25, 2024PUBLISHED FOR OPPOSITION
Tuesday, June 25, 2024OFFICIAL GAZETTE PUBLICATION CONFIRMATION E-MAILED
Tuesday, September 10, 2024REGISTERED-PRINCIPAL REGISTER
Tuesday, September 10, 2024NOTICE OF REGISTRATION CONFIRMATION EMAILED